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group were withdrawn from the study due to raised LFTs or adverse 
events. No serious sequelae resulted from these. One patient in the 
placebo group and two patients in the tacrine group died from causes 
which were considered unrelated to the treatment. 
Condusion: Tacrine produced an improvement that was detected by 
a physician and the patient’s carer. Overall psychometric scores did 
not change, but more patients did better on tacrine than placebo. The 
clinical relevance of these findings varied considerably among patients. 
Doses over 8Cmg tacrine per day may be more effective in patients who 
can tolerate tacrine. 
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CHRONIC LOW DOSE EPTASTIGMINE IN ALZHEIMER PATIENTS: 
RELATIONSHIP BETWEEN ACETYLCHOLINESTERASE INHIBITION 
AND COGNITIVE EFFECTS. B.P. Imbimbo, P.E. Lucchelli. 
Medical Dept., Mediolanum Farmaceutici, Milan, Italy. 
Eptastigmine is a long acting acetylcholinesterase 
(AChE) inhibitor. A double-blind, placebo-controlled, 
multicenter study assessed the safety, tolerability, 
pharmacodynamlcs and preliminary efficacy of multiple 
oral doses of eptastigmine in 100 patients with mild to 
severe Alzheimer's disease. Patients were randomly 
assigned to eptastigmine (30-60 mg/day) or placebo for 
4 weeks at a ratio of 4:l. Red blood cell AChE activity 
was repeatedly measured from 10 uL capillary blood with 
automated device Nine patients dropped out mainly 
it to uncooperati;eness. No hematological adverse 
events occurred. Nineteen patients on eptastigmine had 
cholinergic adverse events associated to peak AChE 
inhibition exceeding 50% after the first dose or 70% at 
steady-state. Four patients had a modest reversible 
increase in liver enzvmes. Thirty-two patients who 
completed an S-week opin extension-phase with the drug 
did not show any significant decrease in neutrophil 
counts. At steady-state, the mean of individual maximum 
values of AChE inhibition was 54 f 2% and was reached 
after 3.1 f 0.6 days. Trough inhibition of AChE 
activity increased during the first four days of 
treatment, reaching a mean value of 23 * 2% at Day 4 
which remained constant throughout the study period (25 
* 1% at Day 29). Mean recovery half-life of enzyme 
activity was 7.5 f 0.9 h. Overall, 31% of the patients 
improved on eptastigmine according to the Physician 
Clinical Global Impression of change versus 0% of the 
patients on placebo (~(0.05). Fifty percent of a 
patient subgroup with 25-35% steady-state AChE 
inhibition showed clinical improvement. Performance on 
both word fluency and logical memory tasks improved 
with an inverted U-shaped relation to average steady- 
state AChE inhibition. This study indicates that daily 
doses of eptastigmine up to 60 mg per day are well 
tolerated and safe even after prolonged treatment. 
Moderate steady-state AChE inhibition is associated to 
maximal cognitive and clinical improvement. 
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CLINlCALANDNJXJROPHYSIOWGICALEVALUATIONOF3DOSESOFS120Z4Z 
(SO, lBO,240 mg o.d.) DURING REPEATED ORAL AD MINBTRATiON (7 days) IN 
12 OIJT-PATIENTSWlTHMlLDTOMODERATEALZHEtMER'SDISEASE. 
C. Demuesn@*. s Remelt***. B. Geermen ??***. hf. vae da Linden*****. L. Lacombler**. P. 
Homey~*, I,. &..**, B. Neunk,*, M.klb&*, 8. B.rr.nden*, D. Geez’ 
*sponser: LRI.9crvicr. 92415 Cwrbevoia sdor. France. **service da Ncumlogie 3, HLwal Piti&9.lp&i&re, 
The cognitive enhancing properlica of Sl2024, which apwrs lo facilitate noredrenergic and 
vasopnsain activity, have been shown for the acquisition and ncall aspects of memory in 
mammsel, monkeys and aged rats. Four randomized placeboanlmlled studies have 
demonstrated good clinical and laboratory tolerability in v~hmteers (up to B single 600 mg 
dose in 90 young and up lo 400 mg/d in 45 elderly during 7 days) and in Alzheimer’s patients 
(n=87) up lo 400 me/d during 28 days, with preliminary evidence of memory cnhanccmenl al 
200 mgld according lo 2 computeri& cognitive esszssmenl systems. 
The objective of this study was to obtain early evidence chat S12024 has potential central 
pbamwolagical activity and cognition enhancing properties in out-patients with mild lo 
moderate Altieimer’s disease. The trial was B monocenter, mndomizsd, pleceba-xnlmlled 
study of lalin square design, wilb 3 oral dosw of 812024-2 (SO, loo, 200 mg ad.), 
administrated during 4 double-blind treatment pcrieds of 7 days, each separated by a Z-week 
wash-x11 period. The cognitive evaluation criteria were MMS. Clinician Interview Based on 
Impression of Change (CIBIC), the Van Der Linden battery of memory and allenliomd 
asswsrnenls (VDL), and fsmily evslustion scales of daily sctivitics. Cognitive testing wss 
performed st the sclcction visit (training session), at the inclusion visit LX (prior to the first 
intake as the baseline) and 1.5 hour after the first intake al DI and after the last intake al D7 
of each period. Quantitative EEG (during a closed eye lest session) and event related potential 
(ERP) (during a selective auditory attention task) were else performed al D7 of each period. 
Twelve patients (mean age: 64 years old +i- IO, mean MMS: 23 +i- 3) completed the study. 
No treatment effect was observed for MMS. VDL bat&v or activities of dailv living sceres. A 
significant period effect was shown al day ; and day 7 between the second and the 4th period 
of treatment for sane items in favor of a learning effst (implicit memory). CIBIC results 
showed B non significant treatment effect in favor of active treatment (100>2~Q>50>0). 
Significant change was observed in qEEG PI and S signals al 200 mg versus placebo (p=O.Ol) 
in favor of nonspecific stimulation of vigilance. A significant difference (p<O.OS) was shown 
b&w-a placebo and Sl2024 concerning the amplitude of the ERP PN signal (“pmcessing 
negativity’). indicating central phamwxdynamic activity without dosczffect relations. 
In summary, S12024 has shown preliminary evidence of central phamucodynnmic activity 
predominantly at 2M) mg/d based on neumphysiological assessments results in favor of some 
influence on vigilance or attention in patients with AD. Good clinical and biological 
tolerability was demonstrated by the parameter stability. The on-going European phase IIb 
study on 300 AD patients located during 3 months will provide more data. 
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PHARMACODYh’AMlC EFFECTS OF REPJZATED ORAL 
ADMtN-ImTION OF 4 D- DOSES OF S12024-2 (Cognitive 
Enhnneer) IN 36 HEALTHY ELDERLY VOLUNTEERS. K. Wesnes", E. 
Neumaa', H.I.G. de Wilde***, M. Malbezin*, H.J.M.J. Crijns***, J.H.G. 
Jonkman**‘, D. Guez’. 
*Sponsor: IRtServicr, 92415 Courbevoie cedex. Frame. ??*CDR Ltd. R&8 RG, 4RB, UK. 
??**ph- &-Research let. B.V., NL-9470 M Zuidlaree, ‘l%e Ned~crlti 
The cognitive potential enhancing properties of S12024, which appears to facilitate 
the activity of brain noradrenalin and vaaopressin, have been found to enhance the 
acquisition and recall of information in marmoset, monkey and aged rats. 
In order to determine whether any evidence of similar effects could be obtained in 
man, the Cognitive Drug Research (CDR) computerized assessment system was 
included in a placebo-controlled double blind, rising dose, tolerance and 
pharmacokinetic trial of the compound in 36 elderly (> 60 years) volunteers. 
The trial was conducted in five sequential stages, in each, 6 volunteers received 
active and 3 placebo medication over 7 days. The doses administered in the four 
stages were twice daily 10, 50, 100 and 200 mg Sl2024-2 respectively. After 4 
training sessions, cognitive testing was performed prior to the morning dosing and 
then at 1.5, 3, 4.5 and 8 hours post-dosing on days 1 and 6. The predosing score on 
day 1 was used as the baseline. The CDR system included assessments of simple and 
choice reaction time, sustained vigilance, memory scanning and delayed recognition 
of words, picture and faces. 
Comparison of the predosing performance ofthis elderly population tothat of 
young control volunteers identified a clear pattern of slowed performance on the 
various attentional and memory tasks. When compared lo placebo, S12024 produced 
a dose-dependent improvement in the speed of recognition performance at the 
intermediate doses (50 and 100 mg t. d.) and to a lesser extent al the 200 mg dose 
level; 10 mg dose was ineffective. 
In conclusion, this study has shown preliminary evidence that S12024-2 is capable 
of correcting age related declines in human cognitive processes in a dose-dependent 
fashion. The study highlights the advantage of including appropriate cognitive early 
in the process of drug evaluation and is promising for the development of S12024-2 
as a cognition enhancer. Further work on the compound is underway to confirm and 
extend these findings (eg. Allain et al, Derouesn6 et al., this conference). 
413 
CAFFEINE ENHANCES MEMORY FUNCTION AFTER CHOLINERGIC 
BLOCKADE. W. Rlcdcl, R.L.A.M. Leboux, E. Hogervorst, A. Quist, A. van der 
Vusse, F.R.J. Verhey and 1. Jolles. Academic Psychiatric Centre, Dept. of 
Psychiatry & Neuropsychology, University of Llmburg, P.O. Box 616, 6200 MD 
Maastricht, Tbc Netherlands. 
A great number of cllnlcal trials have been conducted to assess the efficacy of 
newly developed cognition enhancers in the treatment of Alzbeimer’s Disease as 
well as Age-Associated Memory Impairment. Nevertheless, research has only 
shown minor effects of newly developed substances that should enhance 
connltlon. One of the world’s most widelv used coenltlve enhancers is caffeine. A 
larie postal survey conducted by our departmentr among 2043 normal subjects 
divided over 13 ane arouns rannina from 25-85 Years yielded that the subiects’ 
reported average &lly coifee c%sGmption is loi in tlie youngest age groip (3 
cups /day), gradually increases with age and peaks at 50 yrs (5 cups /day), remains 
constant until 75 yrs (4 cups /day) and diminishes in the two highest age groups (3 
cups /day). 
Nicotine and possibly also caffeine play a protective role in the development of 
dementia. Nicotine’s ability to reverse the scopolamine-induced cognitive 
dysfunction has been demonstrated previously, but caffeine’s hasn’t. Sixteen 
healthy volunteers in the age range of 25-40 years were medically screened and 
treated in accordance with the declaration of Helsinki. They received, on 3 
senarate occasions. weight calibrated doses of 0.5 ma I 75 kn scooolamlne s.c.. 
foilowed one hour late; by the double-blind. double~dummy~plac~bocontrolled 
administration of either 2 mg nicotine in chewing gum, 250 mg caffeine in coffee 
(3 cups), or placebo. Subjects performed a test battery consisting of measures of 
FOURTH INTERNATIONAL CONFERENCE ON ALZHEIMER’S DISEASE SlOl 
oerceotual and osvchomotor speed, information processing, primary and 
‘seconhary memo<y.~memory scatining and focussed and divided aitention, at 1 
hour hefore and 2. 4 and 6 hours after scooolamine administration. The first 
analysis of the performance data shows that scopolamine produced severely 
disturbed memory as well as psychomotor functions. Caffeine significantly 
diminished the impairing effect of scopolamine in the memory tasks. Especially 
secondary memory and delayed recognition parameters were improved after 
caffeine relative to scopolamine alone. This led to the conclusion that (disturbed) 
memory storage, but not retrieval, was positively affected by caffeine. 
Psychomotor performance was not affected by caffeine. The effects of nicotine 
were minor and were less than expected on the basis of previously reported 
studies. Analysis of blood levels can possibly lead to an explanation. 
As far as we know. this is the first demonstration of caffeine’s potential to 
selectivelv enhance memory functioning in subiects who suffer from scopolamine- 
induced -cholinergic dy&nction. Faking into account that caffeine also 
antagonizes hang-over effects of benzodiazepines and that cholinergic 
dysfunction is one of the manifestations of Alzheimer’s Disease, it can be 
concluded that caffeine consumption might be helpful in preventing or 
postponing the symptoms of Alzheiiner’s Disease. . _ _ 
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THERAPY WITH A COMBINATION OF IRON, VITAMIN 86 AND 
COENZYME 010 IN THE LONG TERM FOR SPORADIC 
ALZHEIMER’S DISEASE. Masaki lmagawa MD. Department of 
Neuropsychiatry, Hyogo Prefectural Amagasaki Hospital, 
Hyogo, Japan. 
Of the theraphy with combination of coanzyme Cl10 (CoQlO). vitamin 86 and iron, 
two in the same family were found to have mis-sense mutation of amyroid B-protein 
precursor gene’. This therapy have been tried in 20 patients with the sporadic 
Alzheimer’s disease (AD) in the long term (one year). It is suggested that this 
therapy may be effective for &D. SUBJECTS AND METHODS This clinical study 
included 20 AD. mean f SD age, males 61.8 2 6.8 y.o.. females 61.8 f 6.8 y.o.. 20 
patients have been suffered from AD from 1 year to 7 years. Diagnosis was based 
on DSM- IU -Ft. Mental stage and daily activity were evaluated with mini-mental state 
examination scars (MMSE) and functional assessment stagmg (FAST). And so the 
clinical course was followed by the two methods. These numbers have changed 
accordlng to the severity of the patient’s symptoms and signs. Theses scales were 
marked on the time scale (0. 2 weeks, 1, 3, 6 months, one year). The dose of the 
drugs taken by the patients was iron 50-150 mg. B6 90.180 mg, CoQlO 60-180 mg, 
daily. RESULTS In this therapy, each points have significantly different from zero 
point in scores. In MMSE. 0: 14.6 2 7.0 (11~20). 2W: 22.5 + 5.4 (n=l6)*. 1M: 20.3 f 
5.4 (n=l8)*, 3M: 21.5 + 5.4 (n=20)‘, 6M: 20.3 + 7.1 (n=20)*. 1Y: 21.6 + 6.5 (n=ll)“. 
*, paired t test, p-zO.001. In FAST, the stage have changed from 5 stage (zero point) 
to 3 stage. DISCUSSION Why dose this therapy effect in AD? In general, iron, 
particularly the action of Fe* have a intoxication in viva because of free radicals. But 
iron is essential mineral on the body, especially, brain. Adding to CoQlO, iron 
dependent free radicals may be disappeared. In this therapy it is focus on the 
production of the neurotransmitters through the decarboxylation (B6 B6-enzyme) with 
ATP. 86 is acquires the biosynthesis of GABA. Neuronal cell’s death said to be the 
hypothesis of glutamine iduced cell’s death. Therefore, it IS importance that the 
action of 86 is related with GABA shunt. 
REFERENCE 1. lmagawa M. et al.. &enzyme QlO, iron. and vitamin B6 in 
genetically-confirmed Alzheimer’s disease. LANCET 1992; 340: 671.2 
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NEW POSSIBILITIES IN THE TREATMENT OF PATIENTS WITH 
ALZHEIMER DISEASE. S.A. Groppa, Department of Neurology and 
Neurosurgery, Medical University, Kishinev 277072 Moldova. 
The effect of the drug, dimethylsuifoxid. was studied in 18 patients 
with ‘probable AD’ diagnosed according to NINCDS-ADRDA criteria. 
Patients were repeatedly tested for a period of 9 months. Efficacy was 
estimated from the results of neurological and neurcpsycholcgical 
testing, immunological examination of neurospecific proteins (NSP) 
and autoarrtibodies (AAB) to them. 
The obtained results indicated that the severity of mental-amnestic 
disturbances and disorientaiton in time and space reliably decreased 
after 3 and especially 6 months of treatment. There was also a trend 
for praxic and speech impairments to decrease from baseline. In 
addition, indices of concentration and communicability improved. 
The results of immunoenzyme analysis of NSP and AAB to them 
showed a decrease of NSP serum concentration and a stabilizing 
influence of dimethylsuifoxid on the Mood-brain barrier. 
The action mechanism, dinical efficacy and adverse reactions will be 
discussed. 
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CARDIOVASCULARARpL;TY ~A~II;C$lON&L&F,~DVIOUR IN 
DEMENTED WITH 
POSATIRELIN. SHORT TERM STUDY. D. Cucinotta, S. Costantini, R. 
Del Buono, L. Ambrosoli* and R. Girardello* Geriat. Med. S.Orsola- 
Malpighi University Hospital, Bologna * Res. Dev. Dept. POLI Industria 
Chimica S.p.A., Milan - Italy 
Posatirelin (L-pyre-2-aminoadipyl-L-leucil-prolinamide) is a synthetic 
neuropeptide with neurotrophic activity and modulatory effects on various 
neurotransmission systems. 
This drug is to-day under study in many clinical trials in Europe, 
according to results obtained in preliminary studies in patients suffermg 
from dementia, either of Alzheimer type or vascular origin. 
This double-blind, randomized, short-term clinical trial was carried out 
in order to evaluate the safety profile of Posntirelin on both cardiovascular 
and hormonal parameters. 
24 hrs non invasive ambulato 
monitoring and EKG recording ( or 5 minutes) m 20 patients with 7 
blood pressure, cardiac frequency 
dementia (mild to moderate degree) were determined before and after 
treatments. 10 patients underwent Posafirelin (10 mg daily i.m., 8 days) 
and 10 placebo treatment according to a randomization code. GH release, 
T,, T,, TSH and PRL levels and routine laboratory parameters were 
determined at baseline and at the end of treatment. 9 males and 11 
females 65-80 yrs, mean + SD: 75.10 + 3.7; MMSE score 12-21, mean + 
SD: \ 16.3 f 2.5) entered and completed the study. 
Behavlour of cardiovascular parameters did not show significant 
difference comparing Pomirelin to placebo. Similarly, no changes in the 
EKG were recorded. No significant changes (out of normal biological 
variability) in haematological! serum chemistry or urinanal sis were 
observed. GH concentrationitlme curves, T3, T4, TSH and P t; L levels 
changes were statistically not significant and unrelated to treatment. 
At the end of the treatment (60 minutes after injection) higher values 
of TSH and PRL in Posarireh group than in placebo group were 
observed. This findings have to be verified in further studies, but it is 
necessary to take into consideration that variability was within normal 
ran e of values. 
F he results of this study suggest that Posatirelin may be proposed as a 
safe drug for the treatment of demented elderly patients. 
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CENTRAL SEROMNERGIC HYPERRESPONSIVITY IN 
ALZHEIMER'S DISEASE. D.M.McLoughlin, J.V.Lucey and 
T.G.Dinan. Institute of Psychiatry, London SE5 SAF, 
and Dept. of Psychiatry, Trinity College Medical 
School, Dublin 8, Ireland. 
A wide range of neuroanatomical and biochemical 
deficits have been identified in the central 
serotonergic (S-HT) system in Alzheimer's disease 
(AD). In order to investigate the functional 
significance of these abnormalities the prolactin 
(PRL) response to the 5-HT specific neuroendccrine 
probe d-fenfluramine Cd-FEN) was measured in 9 
patients with late-onset probable AD (NINCDS-ADRDA 
criteria) and in an elderly healthy comparison 
group. PRL levels were measured hourly for 5 hours 
followina an oral dose of 30ms of d-FEN. The PRL 
response- to d-FEN (A PRL) -was calculated by 
subtracting the baseline PRL from the maximum PRL 
level post ingestion of d-FEN. There was no 
significant difference in baseline PRL levels 
between the two groups and the peak PRL response 
occurred in all subjects within 300 mins. The mean 
APRL in the AD group was 209.6(SD=116.9) mtJ/l and 
95.8(SD=53.4) mu/l in the comparison group. The A 
PRL response was significantly greater in the AD 
group (2=2.04, df=16, p=O.O4; Mann-Whitney U test). 
This preliminary study is the first to report an 
enhanced 5-HT neuroendocrine responsivity in late- 
onset AD. 5-HT abnormalities have been implicated in 
depression, anxiety and impulsive, aggressive 
behaviour. 5-HT has also been recognised as having 
an influence, possibly inhibitory, on learning and 
memory. The finding of a functionally 
hyperresponsive 5-HT system in AD could provide a 
rationale for the use of 5-HT antasonists for the 
management of behavioural and cognitive symptoms in 
AD. 
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MANAGING PROBLEM BEHAVIORS ASSOCIATED WITH 
ALZHEIMER’S DISEASE: A PIAGETIAN APPROACH. M.A. Matteson, 
A. Linton, M.J. Lichtenstein, B. Cleary. University of Texas Health Science 
